190 related articles for article (PubMed ID: 33179193)
1. Twenty-four-month results of intravitreal aflibercept for macular edema due to branch retinal vein occlusion.
Sakanishi Y; Yasuda K; Morita S; Mashimo K; Tamaki K; Sakuma T; Ebihara N
Jpn J Ophthalmol; 2021 Jan; 65(1):63-68. PubMed ID: 33179193
[TBL] [Abstract][Full Text] [Related]
2. Outcome of "treat and monitor" regimen of aflibercept and ranibizumab in macular edema secondary to non-ischemic branch retinal vein occlusion.
Pichi F; Elbarky AM; Elhamaky TR
Int Ophthalmol; 2019 Jan; 39(1):145-153. PubMed ID: 29274022
[TBL] [Abstract][Full Text] [Related]
3. Relationship between Recurrence of Macular Edema Due to Branch Retinal Vein Occlusion and Changes in Choroidal Thickness.
Sakanishi Y; Tamaki K; Mashimo K; Sakuma T; Ebihara N
Ophthalmic Res; 2021; 64(3):363-368. PubMed ID: 33070137
[TBL] [Abstract][Full Text] [Related]
4. Comparison between ranibizumab and aflibercept for macular edema associated with central retinal vein occlusion.
Saishin Y; Ito Y; Fujikawa M; Sawada T; Ohji M
Jpn J Ophthalmol; 2017 Jan; 61(1):67-73. PubMed ID: 27660163
[TBL] [Abstract][Full Text] [Related]
5. EFFICACY AND FREQUENCY OF INTRAVITREAL AFLIBERCEPT VERSUS BEVACIZUMAB FOR MACULAR EDEMA SECONDARY TO CENTRAL RETINAL VEIN OCCLUSION.
Lotfy A; Solaiman KAM; Abdelrahman A; Samir A
Retina; 2018 Sep; 38(9):1795-1800. PubMed ID: 28767552
[TBL] [Abstract][Full Text] [Related]
6. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion.
Ding X; Li J; Hu X; Yu S; Pan J; Tang S
Retina; 2011 May; 31(5):838-45. PubMed ID: 21293319
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of intravitreal ziv-aflibercept in patients with macular edema following retinal vein occlusion in Korle-Bu Teaching Hospital, Ghana: a retrospective case series.
Braimah IZ; Agyabeng K; Amoaku WM
Int Ophthalmol; 2021 Jul; 41(7):2445-2453. PubMed ID: 33782846
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of intravitreal bevacizumab for macular edema following branch retinal vein occlusion stratified by baseline visual acuity.
Kim M; Jeong S; Sagong M
Graefes Arch Clin Exp Ophthalmol; 2017 Apr; 255(4):691-697. PubMed ID: 27796671
[TBL] [Abstract][Full Text] [Related]
9. Simultaneous intravitreal dexamethasone and aflibercept for refractory macular edema secondary to retinal vein occlusion.
Giuffrè C; Cicinelli MV; Marchese A; Coppola M; Parodi MB; Bandello F
Graefes Arch Clin Exp Ophthalmol; 2020 Apr; 258(4):787-793. PubMed ID: 31897703
[TBL] [Abstract][Full Text] [Related]
10. Baseline Factors Associated With 6-Month Visual Acuity and Retinal Thickness Outcomes in Patients With Macular Edema Secondary to Central Retinal Vein Occlusion or Hemiretinal Vein Occlusion: SCORE2 Study Report 4.
Scott IU; VanVeldhuisen PC; Ip MS; Blodi BA; Oden NL; King J; Antoszyk AN; Peters MA; Tolentino M;
JAMA Ophthalmol; 2017 Jun; 135(6):639-649. PubMed ID: 28492860
[TBL] [Abstract][Full Text] [Related]
11. Twenty-Four-Month Results of Intravitreal Bevacizumab in Macular Edema Secondary to Branch Retinal Vein Occlusion.
Tsagkataki M; Papathomas T; Lythgoe D; Kamal A
Semin Ophthalmol; 2015; 30(5-6):352-9. PubMed ID: 24875368
[TBL] [Abstract][Full Text] [Related]
12. Association of Disorganization of Retinal Inner Layers With Visual Acuity Response to Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Secondary to Retinal Vein Occlusion.
Babiuch AS; Han M; Conti FF; Wai K; Silva FQ; Singh RP
JAMA Ophthalmol; 2019 Jan; 137(1):38-46. PubMed ID: 30286219
[TBL] [Abstract][Full Text] [Related]
13. Intravitreal Aflibercept for Macular Edema Following Branch Retinal Vein Occlusion: 52-Week Results of the VIBRANT Study.
Clark WL; Boyer DS; Heier JS; Brown DM; Haller JA; Vitti R; Kazmi H; Berliner AJ; Erickson K; Chu KW; Soo Y; Cheng Y; Campochiaro PA
Ophthalmology; 2016 Feb; 123(2):330-336. PubMed ID: 26522708
[TBL] [Abstract][Full Text] [Related]
14. Prospective study of aflibercept for the treatment of persistent macular oedema secondary to retinal vein occlusions in eyes not responsive to long-term treatment with bevacizumab or ranibizumab.
Spooner K; Fraser-Bell S; Hong T; Chang A
Clin Exp Ophthalmol; 2020 Jan; 48(1):53-60. PubMed ID: 31498950
[TBL] [Abstract][Full Text] [Related]
15. Effects of intravitreal injection of ranibizumab and aflibercept for branch retinal vein occlusion on the choroid: a retrospective study.
Kishishita S; Sakanishi Y; Morita S; Matsuzawa M; Usui-Ouchi A; Ebihara N
BMC Ophthalmol; 2022 Nov; 22(1):458. PubMed ID: 36447155
[TBL] [Abstract][Full Text] [Related]
16. Aflibercept Treatment for Macular Edema following Branch Retinal Vein Occlusion: Age-Based Responses.
Sırakaya E; Küçük B; Ağadayı A
Ophthalmologica; 2020; 243(2):94-101. PubMed ID: 31461723
[TBL] [Abstract][Full Text] [Related]
17. Macular vessel reduction as predictor for recurrence of macular oedema requiring repeat intravitreal ranibizumab injection in eyes with branch retinal vein occlusion.
Hasegawa T; Takahashi Y; Maruko I; Kogure A; Iida T
Br J Ophthalmol; 2019 Oct; 103(10):1367-1372. PubMed ID: 30514711
[TBL] [Abstract][Full Text] [Related]
18. Intravitreal bevacizumab and cytokine levels in major and macular branch retinal vein occlusion.
Lim JW
Ophthalmologica; 2011; 225(3):150-4. PubMed ID: 21150231
[TBL] [Abstract][Full Text] [Related]
19. Bevacizumab versus bevacizumab and macular grid photocoagulation for macular edema in eyes with non-ischemic branch retinal vein occlusion: results from a prospective randomized study.
Callizo J; Atili A; Striebe NA; Bemme S; Feltgen N; Hoerauf H; Bertelmann T
Graefes Arch Clin Exp Ophthalmol; 2019 May; 257(5):913-920. PubMed ID: 30610424
[TBL] [Abstract][Full Text] [Related]
20. Intravitreal ranibizumab for macular oedema secondary to retinal vein occlusion: a retrospective study of 34 eyes.
Puche N; Glacet A; Mimoun G; Zourdani A; Coscas G; Soubrane G
Acta Ophthalmol; 2012 Jun; 90(4):357-61. PubMed ID: 20602625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
